drugset / Trial / NCT07272889

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

NCT07272889

Phase 1 Completed 24 enrolled Atea Pharmaceuticals, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Drug-drug interaction study between Ethinyl Estradioll/Levonorgestrel and Bemnifosbuvir/Ruzasvir

Timeline

Start
2025-12-04
Primary completion
2026-02-17
Completion
2026-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified 550 mg Oral
Subject Levonorgestrel Small molecule 0.15 mg Oral
Subject Ruzasvir Other / unclassified 180 mg Oral
Subject ethinyl estradiol Small molecule 0.03 mg Oral

Indications

No indication recorded.